Here are four things to know:
1. Organogenesis will become a wholly owned subsidiary of Avista.
2. Avista Capital Partners’ affiliates agreed to invest $92 million in the combined company in conjunction with the transaction.
3. The combined company’s anticipated initial enterprise value is approximately $673 million.
4. Organogenesis offers bioactive and acellular biomaterials products in advanced wound care, sports medicine and surgical biologics, including orthopedics and spine.
More articles on biologics:
6 things to know about Isto Biologics
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
Vericel appoints CMO: 3 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
